Related Experiment Videos
Neurological effects of recombinant human interferon
British Medical Journal (Clinical Research Ed.)
|January 22, 1983
Summary
Recombinant leucocyte interferon treatment for advanced breast cancer caused significant side effects, including flu-like symptoms, fatigue, and neurological issues. These adverse events resolved upon dose reduction or discontinuation of the interferon therapy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Advanced locally recurrent breast cancer presents a therapeutic challenge.
- Patients often fail to respond to conventional treatments like radiation, hormonal, and cytotoxic agents.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant leucocyte interferon in patients with advanced breast cancer.
- To document the side effects associated with interferon therapy in this patient population.
Main Methods:
- Ten women with advanced locally recurrent breast cancer received recombinant leucocyte interferon (20 x 10(6) U/m2 daily or 50 x 10(6) U/m2 thrice weekly) for up to 12 weeks.
- Adverse events and neurological changes (including EEG) were monitored throughout the treatment period.
Main Results:
- All patients experienced influenza-like symptoms within an hour of administration.
- Common side effects included lethargy, anorexia, nausea, weight loss, somnolence, and confusion.
- One patient developed signs of an upper motor neurone lesion; EEG showed increased slow wave activity in all patients.
Conclusions:
- Recombinant leucocyte interferon treatment for advanced breast cancer is associated with significant, dose-dependent side effects.
- These adverse events, including neurological and systemic symptoms, were reversible upon dose reduction or cessation of therapy.
- Further studies are warranted to elucidate the mechanisms underlying these interferon-induced effects.